Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Gene expression profiles of patients with multiple myeloma who have been treated previously


ABSTRACT: This Series represents the gene expression profiles of patients with multiple myeloma who have been treated previously. In brief, Total Therapy 6 (TT6) is an open label phase 2 protocol for patients with symptomatic multiple myeloma, who had been treated with more than one cycle of prior therapy excluding autologous hematopoietic stem cell transplant. This protocol was approved by the institutional review board on March 25, 2009 (IRB#108053). The TT6 treatment regimen consists of induction therapy with Melphalan/Bortezomib/Thalidomide/Dexamethasone/Cisplatin/Doxorubicin/Cyclophosphamide/Etoposide (M-VTD-PACE) followed by a high dose M-VTD-PACE based tandem transplant. Maintenance therapy consists of Bortezomib/Lenalidomide/Dexamethasone alternating with Borteomib/Melphalan/Dexamethasone every months for 3 years. We analyzed CD138+ selected cells of previously treated MM patients by microarray.

ORGANISM(S): Homo sapiens

SUBMITTER: Christoph Heuck 

PROVIDER: E-GEOD-57317 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

altmetric image

Publications

Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma.

Heuck C J CJ   Qu P P   van Rhee F F   Waheed S S   Usmani S Z SZ   Epstein J J   Zhang Q Q   Edmondson R R   Hoering A A   Crowley J J   Barlogie B B  

Leukemia 20140731 12


Similar Datasets

2015-01-20 | GSE57317 | GEO
2015-12-31 | E-GEOD-69028 | biostudies-arrayexpress
2015-12-31 | E-GEOD-68871 | biostudies-arrayexpress
2014-12-23 | E-GEOD-58133 | biostudies-arrayexpress
2012-11-05 | E-GEOD-38627 | biostudies-arrayexpress
2014-12-23 | GSE58133 | GEO
2015-12-31 | GSE69028 | GEO
2015-12-31 | GSE68871 | GEO
2018-06-28 | GSE116324 | GEO
2008-06-13 | E-GEOD-2658 | biostudies-arrayexpress